| 1. | In the placebo group , no significant changes of symptoms were recorded
而在安慰剂组，实验前后没有观察到明显的症状改善。 |
| 2. | Treatment duration was a median of 23 weeks in the sorafenib group and 19 weeks in the placebo group
治疗时间中位数在索拉非尼组为23周，在安慰剂组为19周。 |
| 3. | Patients who supplemented with pycnogenol ? also had increased antioxidant levels compared to the placebo group
服用碧萝芷?治疗的患者的抗氧化水平也较安慰剂组有所提高。 |
| 4. | The incidence of aderse effects was similar between the 25 - mg , 50 - mg , and placebo groups but higher in the 100 - mg group
在25毫克组， 50毫克组以及安慰剂组中的不良反应发生率相似，但在100毫克组中较高。 |
| 5. | None of the studies reported serious side effects , and rates of sinusitis relapse were similar between the treatment and placebo groups
这些研究均没有报道严重的副作用，并且鼻窦炎的复发率与安慰剂治疗组相类似。 |
| 6. | In contrast to the placebo group a progressive increase of total and free tfpi was determined after the administration of the mps cream
与安慰剂组不同的是，多磺酸粘多糖乳膏组，总的和游离的组织因子旁路抑制因子（ tfpi ）水平持续增加。 |
| 7. | Results showed that when patients were lying down , pycnogenol ? treatment improved capillary blood flow by 34 percent , compared to 4 . 7 percent in the placebo group
实验结果表明，当病人平躺时，碧萝芷?组病人的的血流速度提高了37 % ，而安慰剂组仅提高了4 . 7 % 。 |
| 8. | When patient ' s blood flow was measured in a standing position , pycnogenol ? treatment improved capillary blood flow by 68 percent , compared to 8 percent in the placebo group
当在病人站立状态进行血流速度测量时，碧萝芷?组病人毛细血管的血流速度提高了68 % ，而安慰剂组仅提高了8 % 。 |
| 9. | The good news , the editorial writers say , is that women in the placebo group experienced about a 30 percent reduction in seerity and frequency of symptoms during the 12 - month follow - up period
好消息是，社论作者说，安慰剂试验组的妇女在12个月的随访期间，频繁和严重的症状减少了30 。 |
| 10. | " for every 100 patients treated with intranasal corticosteroids , seven additional patients had complete or marked symptom relief , " compared to those in the placebo group , the reviewers found
评论家比较这些研究对照组发现： “每一百名接受鼻内皮质类固醇治疗的患者中，就额外又多出七名患者的症状得到显著减轻或完全缓解。 ” |
